Newsfeeds - Spark Newswire

1 minute read

Mersana Inks Cancer Therapy Development Deal With Merck Germany

Today, 11:52 AM

Mersana Therapeutics Inc (NASDAQ:MRSN) signed a deal for developing antibody-drug conjugates (ADCs) for cancer treatment with Germany’s Merck KGaA (OTC:MKGAF) (OTC:MKKGY). Mersana would…

MKGAF

1 minute read

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact

By Vandana Singh

Today, 11:52 AM

Merck KGaA (OTC:MKGAF) and GlaxoSmithKline Plc (NASDAQ:GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said the move was…

GSK

1 minute read

Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial

By Vandana Singh

Today, 11:52 AM

Merck KGaA’s (OTC:MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring…

GSK

2 minute read

Immutep Announced New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti

By Charles Gross

Today, 11:52 AM

Immutep Limited (NASDAQ: IMMP) announces a new collaboration and supply agreement with Merck KGaA , Darmstadt, Germany (OTC: MKGAF) for a Phase I/IIa clinical trial in patients with solid tumours, calledINSIGHT-005.

IMMP

1 minute read

Uncategorized

Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share

By Vandana Singh

Today, 11:52 AM

Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of…

MKGAF

2 minute read

Uncategorized

UK’s NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA’s Bavencio As First-Line Therapy For Bladder Cancer

By Vandana Singh

Today, 11:52 AM

England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTC:MKGAF) Bavencio (avelumab) as first-line maintenance therapy for…

MKGAF

Latest news

Mersana Inks Cancer Therapy Development Deal With Merck Germany

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact

Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial

Immutep Announced New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti

Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share

UK’s NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA’s Bavencio As First-Line Therapy For Bladder Cancer